Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Lyne

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 20, 2007
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisGary R Lichtenstein, Michael A Kamm, Prabhakar Boddu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 22, 2013
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderDavid Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Gastroenterology|January 24, 2007
Once-daily, high-concentration MMX mesalamine in active ulcerative colitisMichael A Kamm, William J Sandborn, Miguel Gassull, et al.
CNS Drugs|August 21, 2013
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb studyRalf W Dittmann, Esther Cardo, Peter Nagy, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|May 21, 2014
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study designDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|February 13, 2016
Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy studyJeffrey H Newcorn, Valerie Harpin, Michael Huss, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 20, 2007
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisGary R Lichtenstein, Michael A Kamm, Prabhakar Boddu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 22, 2013
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderDavid Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Gastroenterology|January 24, 2007
Once-daily, high-concentration MMX mesalamine in active ulcerative colitisMichael A Kamm, William J Sandborn, Miguel Gassull, et al.
CNS Drugs|August 21, 2013
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb studyRalf W Dittmann, Esther Cardo, Peter Nagy, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|May 21, 2014
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study designDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|February 13, 2016
Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy studyJeffrey H Newcorn, Valerie Harpin, Michael Huss, et al.
Pageof 3